Detalles de la búsqueda
1.
Decitabine in Older Patients with AML: Quality of Life Results of the EORTC-GIMEMA-GMDS-SG Randomized Phase III Trial.
Blood
; 2024 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38717861
2.
Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial.
Am J Hematol
; 99(3): 486-489, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38174977
3.
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Blood
; 138(26): 2753-2767, 2021 12 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34724563
4.
Towards a personalized preventive strategy of Herpes zoster infection in patients with hematologic diseases or hematopoietic stem cell transplant recipients: a position paper from an ad hoc Italian expert panel.
Haematologica
; 2023 Dec 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38105723
5.
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.
Am J Hematol
; 98(12): 1847-1855, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37671649
6.
ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms.
Future Oncol
; 19(2): 103-111, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36651780
7.
Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML.
Int J Mol Sci
; 24(4)2023 Feb 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36834477
8.
Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group.
Br J Haematol
; 199(4): 507-519, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35945164
9.
Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial.
Haematologica
; 107(12): 2823-2833, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35295076
10.
Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study.
Hematol Oncol
; 40(5): 857-863, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35932208
11.
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV.
Hematol Oncol
; 40(5): 846-856, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35854643
12.
Pneumocystis jirovecii pneumonia in patients with previously untreated acute myeloid leukaemia.
Mycoses
; 65(2): 233-238, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34883533
13.
Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters.
Br J Haematol
; 193(1): 129-132, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32808672
14.
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies.
Br J Haematol
; 195(3): 371-377, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34272724
15.
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.
Blood
; 134(12): 935-945, 2019 09 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31395600
16.
Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the Campus ALL Network.
Haematologica
; 106(1): 39-45, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31879328
17.
AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial.
Future Oncol
; 17(29): 3787-3796, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34254530
18.
Detection and management of acute myeloid leukemia measurable residual disease: is it standard of care?
Curr Opin Hematol
; 27(2): 81-87, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31895104
19.
In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab.
Int J Cancer
; 146(1): 236-247, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31479522
20.
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Blood
; 131(12): 1275-1291, 2018 03 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-29330221